Overview
Celemics’ BRCA 1,2 Target Enrichment Panel is designed to enrich
whole coding sequences (CDS) of the BRCA1 and BRCA2 genes
including UTR, promoter, and +/- 40 bases of CDS to detect
the variants in the splicing site.
of variants including large indel and CNV. High performance of the panel guarantees reliable and consistent sequencing results
to customers even if using DNA from low-quality clinical samples or FFPE. Additionally, Celemics provides clinical-grade reports from our proprietary bioinformatics
pipeline and in conjunction with Strand Life Sciences.

Features &
Benefits
-
- Targets the whole CDS (+/- 40) and promoter regions of
BRCA 1,2 with high specificity -
Target regions not only cover CDS regions, but are expanded by ±40 of CDS
to detect splicing site variants. - Probes specifically designed for detecting deletion, duplication,
and large rearrangement
- Targets the whole CDS (+/- 40) and promoter regions of
-
- Compatible with a variety of sample types
- No compromise on panel performance regardless of specimen types, even for challenging ones such as blood or FFPE
-
- Market leading panel performance in uniformity and coverage
- Designed to target the whole exon regions of BRCA 1, 2 gene with 100%
coverage (RefSeq) and validated to yield 100% coverage
-
- Clinical grade performance
- CE-IVD certified target enrichment panel
- Greater than 95% sensitivity and 99.5% specificityfor all types of mutations (SNV and Indel)
-
- Provision of Bioinformatics SW
- FASTQ to annotated VCF
- Clinical grade report
- EU-GDPR compliant through usage of Europe-based server
Performance
Market leading panel performance in Uniformity and Coverage Comparison data with competitors' products
- The extremely low standard deviation of uniformity enables consistent and reliable sequencing results
- In-house test of the panel shows 100% of coverage for all target regions including whole CDS (+/- 40 bp), UTR, and promoter region
User-friendly analysis report with information of all types of variants and CNV

- The extremely low standard deviation of uniformity enables consistent and reliable sequencing results
- In-house testing of the panel indicated 100% coverage for all target regions including whole CDS (±40 bp), UTR, and promoter region
Applications
-
Breast and Ovarian cancer related fields